Download PDF
Digestive Disease Interventions 2020; 04(01): 031-035
DOI: 10.1055/s-0040-1705096
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma

Martin I. Montenovo 
1   Division of Hepatobiliary Surgery, Liver Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee
› Author Affiliations
Further Information

Publication History

09 September 2019

10 January 2020

Publication Date:
02 March 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related death. Despite the significant progress that has been achieved with local therapies, treatment remains limited by impaired liver function and high rate of recurrence. The purpose of the manuscript is to describe the current status of using living donor liver transplantation in patients with advanced HCC.

Keywords

HCC - liver transplantation - living donation
 

  • References

  • 1 Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 2014; 19 (03) 229-234
    CrossrefPubMedGoogle Scholar
  • 2 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 3 Pomfret EA, Lodge JP, Villamil FG, Siegler M. Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl 2011; 17 (Suppl. 02) S128-S132
    CrossrefPubMedGoogle Scholar
  • 4 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008; 8 (04) 839-846
    CrossrefPubMedGoogle Scholar
  • 5 Yao FY, Ferrell L, Bass NM. , et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    CrossrefPubMedGoogle Scholar
  • 6 Mazzaferro V, Llovet JM, Miceli R. , et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 7 Lee SG, Hwang S, Moon DB. , et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14 (07) 935-945
    CrossrefPubMedGoogle Scholar
  • 8 Toso C, Trotter J, Wei A. , et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14 (08) 1107-1115
    CrossrefPubMedGoogle Scholar
  • 9 Zheng SS, Xu X, Wu J. , et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85 (12) 1726-1732
    CrossrefPubMedGoogle Scholar
  • 10 DuBay D, Sandroussi C, Sandhu L. , et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253 (01) 166-172
    CrossrefPubMedGoogle Scholar
  • 11 Shirabe K, Taketomi A, Morita K. , et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant 2011; 25 (05) E491-E498
    CrossrefPubMedGoogle Scholar
  • 12 Kaido T, Ogawa K, Mori A. , et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154 (05) 1053-1060
    CrossrefPubMedGoogle Scholar
  • 13 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014; 3 (02) 108-118
    CrossrefPubMedGoogle Scholar
  • 14 Kim JM, Kwon CH, Joh JW. , et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2014; 46 (03) 726-729
    CrossrefPubMedGoogle Scholar
  • 15 Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003; 9 (07) 700-702
    CrossrefPubMedGoogle Scholar
  • 16 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7 (04) 649-661
    CrossrefPubMedGoogle Scholar
  • 17 Fisher RA, Kulik LM, Freise CE. , et al; A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7 (06) 1601-1608
    CrossrefPubMedGoogle Scholar
  • 18 Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94 (01) 78-86
    CrossrefPubMedGoogle Scholar
  • 19 Gondolesi GE, Roayaie S, Muñoz L. , et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239 (02) 142-149
    CrossrefPubMedGoogle Scholar
  • 20 Hwang S, Lee SG, Ahn CS. , et al. Small-sized liver graft does not increase the risk of hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc 2007; 39 (05) 1526-1529
    CrossrefPubMedGoogle Scholar
  • 21 Lee EC, Kim SH, Shim JR, Park SJ. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond Milan criteria. Liver Transpl 2018; 24 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 22 Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16 (08) 925-929
    CrossrefPubMedGoogle Scholar
  • 23 Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl 2014; 20 (09) 1045-1056
    CrossrefPubMedGoogle Scholar
  • 24 Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014; 20 (08) 937-944
    CrossrefPubMedGoogle Scholar
  • 25 Mehta N, Heimbach J, Lee D. , et al. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time “sweet spot”. Transplantation 2017; 101 (09) 2071-2078
    CrossrefPubMedGoogle Scholar
  • 26 Otto G, Herber S, Heise M. , et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12 (08) 1260-1267
    CrossrefPubMedGoogle Scholar
  • 27 Vitale A, D'Amico F, Frigo AC. , et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17 (09) 2290-2302
    CrossrefPubMedGoogle Scholar
  • 28 DiNorcia J, Florman SS, Haydel B. , et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma. Analysis from the US multicenter HCC transplant consortium. Ann Surg 2019; 10: 1-9
    PubMedGoogle Scholar
  • 29 Agopian VG, Harlander-Locke MP, Ruiz RM. , et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation. Analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg 2017; 266 (03) 525-535
    CrossrefPubMedGoogle Scholar
  • 30 Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233 (05) 652-659
    CrossrefPubMedGoogle Scholar
  • 31 Jonas S, Bechstein WO, Steinmüller T. , et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33 (05) 1080-1086
    CrossrefPubMedGoogle Scholar
  • 32 Tamura S, Kato T, Berho M. , et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136 (01) 25-30 , discussion 31
    PubMedGoogle Scholar
  • 33 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22 (01) 232-252
    CrossrefPubMedGoogle Scholar
  • 34 Yang SH, Suh KS, Lee HW. , et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141 (05) 598-609
    CrossrefPubMedGoogle Scholar
  • 35 Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49 (03) 832-838
    CrossrefPubMedGoogle Scholar
  • 36 Shirabe K, Kajiyama K, Abe T. , et al. Predictors of microscopic portal vein invasion by hepatocellular carcinoma: measurement of portal perfusion defect area ratio. J Gastroenterol Hepatol 2009; 24 (08) 1431-1436
    CrossrefPubMedGoogle Scholar
  • 37 Eguchi S, Takatsuki M, Hidaka M. , et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 2010; 34 (05) 1034-1038
    CrossrefPubMedGoogle Scholar
  • 38 Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010; 102 (05) 462-468
    CrossrefPubMedGoogle Scholar
  • 39 Yang SH, Suh KS, Lee HW. , et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12 (11) 1655-1660
    CrossrefPubMedGoogle Scholar
  • 40 Seo S, Hatano E, Higashi T. , et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13 (2 Pt 1): 427-433
    CrossrefPubMedGoogle Scholar
  • 41 Kornberg A, Freesmeyer M, Bärthel E. , et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009; 9 (03) 592-600
    CrossrefPubMedGoogle Scholar
  • 42 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. ; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22
    CrossrefPubMedGoogle Scholar
  • 43 Shimamura T, Akamatsu N, Fujiyoshi M. et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule – a retrospective study. Transp Int 2019; 32: 356-368
    PubMedGoogle Scholar